Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.
about
Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions.Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls.The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.TNF-alpha and adipocyte biology.Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.Immunological priming attenuates the in vivo pathophysiological response to lipopolysaccharide. Comparison of cytokine production, tissue injury, and lethality in complete Freund's adjuvant-primed mice and in unprimed mice.Humoral mediation for cachexia in tumour-bearing rats.Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes.Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activityC-terminal truncated forms of Met, the hepatocyte growth factor receptorTumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivoSuppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancerThe inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cellsTrovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.Impact of long-term high-intensity interval and moderate-intensity continuous training on subclinical inflammation in overweight/obese adults.Role of TNF superfamily ligands in innate immunity.Ceramide mediates inhibition of the renal epithelial sodium channel by tumor necrosis factor-alpha through protein kinase C.Transactivation of human immunodeficiency virus type 1 long terminal repeats by cell surface tumor necrosis factor alpha.Differential effects of hyperthermia on macrophage interleukin-6 and tumor necrosis factor-alpha expression.Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains of Porphyromonas gingivalis.Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.
P2860
Q30443950-88926C55-D53B-481B-9F66-8E1440308C45Q33918736-ECB3B2CD-5BD3-4A82-B649-AD880F4B74E7Q34607576-AAFE7235-B4EC-4221-B433-DCA32C0AC6D1Q35006572-380D679F-D0A6-4449-A0FF-EC318C4A6BC2Q35714438-A945BE56-905A-4BAB-A33D-6157C358DE99Q35833307-ED13A144-64FF-41B3-AF0A-7662C30B900BQ35975846-09128AAE-6D95-4448-9DD4-F3E0A768BA69Q36361402-16AA5E7B-75DA-485A-A7F5-BF2612AFEB2DQ36364492-B4036DCF-FF7D-43FB-8D6E-0ADFF34B8D4DQ36627020-793CB74D-4E3B-49B8-8DD4-20DF45F0D3C0Q36743037-11BFD04C-E964-4CF5-8542-029EC5666755Q37031936-03D140B9-B1A7-409F-A8CC-34988D497806Q37040443-6939176F-536B-40DF-A261-04DD088116C0Q37288834-5237034A-7855-454B-B3A0-B3A07882A46EQ37343343-0F5A67E0-E2B2-488D-973E-F4414052CE85Q37581328-F689B0F5-D840-4D7A-B1BB-9178368B8E98Q37895960-D14C4037-A4A2-4BBE-8ED5-BA0A902D0887Q40106761-E6C7310F-BEF3-451B-9509-6C3D994A1ED5Q40115290-C896A1A8-345C-4235-B6F9-A5F348521766Q40702135-421D1F98-753B-49AB-8ABB-DB6E51284F6CQ41013333-EF984DBA-3F25-4C5F-9886-5B8C63B04A19Q46949914-56A8E0FB-6704-468F-9162-B46851A6ED6EQ48237143-84105C56-8185-4C38-ABDF-86D1B988AF85
P2860
Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Purification and characterizat ...... ates of human cancer patients.
@ast
Purification and characterizat ...... ates of human cancer patients.
@en
type
label
Purification and characterizat ...... ates of human cancer patients.
@ast
Purification and characterizat ...... ates of human cancer patients.
@en
prefLabel
Purification and characterizat ...... ates of human cancer patients.
@ast
Purification and characterizat ...... ates of human cancer patients.
@en
P2093
P2860
P356
P1476
Purification and characterizat ...... ates of human cancer patients.
@en
P2093
Cappuccini F
Gatanaga T
Granger GA
Lucci JA 3rd
Yamamoto RS
P2860
P304
P356
10.1073/PNAS.87.22.8781
P407
P577
1990-11-01T00:00:00Z